Clinical Trials Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. May 21, 2015; 21(19): 5979-5984
Published online May 21, 2015. doi: 10.3748/wjg.v21.i19.5979
Table 1 Doses and treatment schedules for each level
GemcitabineCisplatinS-1 (mg/d, Days 1-7, 15-21)
(mg/m2, Days 1, 15)BSA < 1.251.25 < BSA < 1.5BSA > 1.5
Level -1800206080100
Level 0800256080100
Level 11000256080100
Level 210002580100120
Table 2 Patient characteristics
Characteristicn (%)
Sex
Male10 (83)
Female2 (17)
Median age69 (range 44-77)
Primary lesion
Intrahepatic2 (17)
Extrahepatic3 (25)
Gallbladder7 (58)
Ampulla of vater0 (0)
Disease status
Unresectable12 (100)
Recurrent0 (0)
Performance status (0/1)12/0
Biliary drainage6 (50)
Median CEA (ng/mL)3 (range 1.1-33.4)
Median CA19-9 (U/mL)156.5 (range 1.0- > 10000)
Table 3 Dose-limiting toxicities at each level
LevelAgeSexPrimary lesionBiliary drainageDLTResponse (RECIST)
071MExtrahepaticYesNonePR
073MExtrahepaticYesNoneSD
063FGallbladderNoNonePD
177MIntrahepaticYesGr 4 febrile neutropenia and leucopenia, Gr 3 thrombocytopeniaPD
167MGallbladderYesNoneNE
164MGallbladderNoNoneSD
170MExtrahepaticYesNoneSD
172MGallbladderNoNonePR
174MGallbladderNoNonePR
258MIntrahepaticNoNonePR
268FGallbladderNoNoneSD
244MGallbladderYesNonePD
Table 4 Hematologic adverse events during the first cycle
Level 0(n = 3)Level 1(n = 6)Level 2(n = 3)
Gr 1-2Gr 3-4Gr 1-2Gr 3-4Gr 1-2Gr 3-4
Neutropenia000101
Leucopenia102110
Thrombocytopenia201100
Anemia201000
Febrile neutropeniaNA0NA1NA0
Table 5 Non-hematologic adverse events during the first cycle
Level 0(n = 3)Level 1(n = 6)Level 2(n = 3)
Gr 1-2Gr 3-4Gr 1-2Gr 3-4Gr 1-2Gr 3-4
Anorexia201020
Nausea101000
Vomiting100000
Fatigue000020
Constipation101000
Fever102000
Biliary tract infectionNA3NA0NA1
Infections (others)000200
AST302000
ALT202000
Hyperbilirubinemia201010
Creatinine003000